PL371264A1 - Sposób leczenia chorób kości - Google Patents

Sposób leczenia chorób kości

Info

Publication number
PL371264A1
PL371264A1 PL02371264A PL37126402A PL371264A1 PL 371264 A1 PL371264 A1 PL 371264A1 PL 02371264 A PL02371264 A PL 02371264A PL 37126402 A PL37126402 A PL 37126402A PL 371264 A1 PL371264 A1 PL 371264A1
Authority
PL
Poland
Prior art keywords
treatment
bone disorders
risedronate
polymorph
solvate
Prior art date
Application number
PL02371264A
Other languages
English (en)
Inventor
Pamela Jean Schofield
Den Berg Henry Van
David Ernest Burgio
Arkadi Aaron Chines
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23352430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL371264(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Publication of PL371264A1 publication Critical patent/PL371264A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL02371264A 2001-12-21 2002-12-16 Sposób leczenia chorób kości PL371264A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34487501P 2001-12-21 2001-12-21

Publications (1)

Publication Number Publication Date
PL371264A1 true PL371264A1 (pl) 2005-06-13

Family

ID=23352430

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02371264A PL371264A1 (pl) 2001-12-21 2002-12-16 Sposób leczenia chorób kości

Country Status (24)

Country Link
US (5) US20030118634A1 (pl)
EP (1) EP1455796A1 (pl)
JP (1) JP2005514400A (pl)
KR (1) KR100638122B1 (pl)
CN (1) CN100479823C (pl)
AR (1) AR038041A1 (pl)
AU (1) AU2002360619B2 (pl)
CA (1) CA2469779C (pl)
CZ (1) CZ2004690A3 (pl)
HK (1) HK1087039A1 (pl)
HU (1) HUP0402267A3 (pl)
IL (2) IL162053A0 (pl)
MA (1) MA27157A1 (pl)
MX (1) MXPA04006027A (pl)
MY (1) MY147886A (pl)
NO (1) NO340249B1 (pl)
NZ (1) NZ532994A (pl)
PE (1) PE20030743A1 (pl)
PL (1) PL371264A1 (pl)
RU (1) RU2294203C2 (pl)
SK (1) SK2532004A3 (pl)
TW (1) TWI349553B (pl)
WO (1) WO2003055496A1 (pl)
ZA (1) ZA200404007B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1455796A1 (en) * 2001-12-21 2004-09-15 The Procter & Gamble Company Method for the treatment of bone disorders
DK1506041T3 (da) * 2002-05-10 2008-01-28 Hoffmann La Roche Inbandronsyre til behandling og forebyggelse af osteoporose
US20040097468A1 (en) * 2002-11-20 2004-05-20 Wimalawansa Sunil J. Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
PT1790347E (pt) * 2002-12-20 2015-02-05 Hoffmann La Roche Formulação de ibandronato a dose elevada
RS51562B (en) * 2004-05-24 2011-08-31 Warner Chilcott Company Llc. ENTERICAL SOLID ORAL DOSAGE FOR BISPHOSPHONATES CONTAINING HELAT
WO2006020009A1 (en) * 2004-07-23 2006-02-23 The Procter & Gamble Company Solid oral dosage form of a bisphosphonate containing a chelating agent
US20070191315A1 (en) * 2006-02-16 2007-08-16 Bengt Bergstrom Method for administering ibandronate

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA777769A (en) * 1963-03-18 1968-02-06 H. Roy Clarence Substituted methylene diphosphonic acid compounds and detergent compositions
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
DE2534391C2 (de) * 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
DE2745083C2 (de) * 1977-10-07 1985-05-02 Henkel KGaA, 4000 Düsseldorf Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung
US4252742A (en) * 1979-07-13 1981-02-24 Ciba-Geigy Corporation Chemical process for the preparation of 2,6-dialkylcyclohexylamines from 2,6-dialkylphenols
DE2943498C2 (de) * 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure
DE3016289A1 (de) * 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
FR2531088B1 (fr) * 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
DE3434667A1 (de) * 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
IT1196315B (it) * 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
US4812311A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
DE3512536A1 (de) * 1985-04-06 1986-10-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE3540150A1 (de) * 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3626058A1 (de) * 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3640938A1 (de) * 1986-11-29 1988-06-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel
CA1339805C (en) * 1988-01-20 1998-04-07 Yasuo Isomura (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active
EP0333082A3 (en) * 1988-03-15 1991-05-02 Takeda Chemical Industries, Ltd. Cephem compounds, their production and use
GB2217988B (en) * 1988-04-11 1992-04-01 Gould Leonard W Regimen for increasing bone density in humans
DE3822650A1 (de) * 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5018651A (en) * 1988-12-27 1991-05-28 Hull Harold L Side or end dump article carrier
DE3917153A1 (de) * 1989-05-26 1990-11-29 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
NL8902727A (nl) * 1989-11-06 1991-06-03 Philips Nv Objecthouder voor ondersteuning van een object in een geladen deeltjesbundelsysteem.
US5356887A (en) * 1990-01-31 1994-10-18 Merck & Co., Inc. Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
TW237386B (pl) * 1992-04-15 1995-01-01 Ciba Geigy
US5391743A (en) * 1992-05-29 1995-02-21 Procter & Gamble Pharmaceuticals, Inc. Quaternary nitrogen-containing phosphonate compounds, pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism and methods of treating and preventing dental calculus and plaque
ES2118967T3 (es) * 1992-05-29 1998-10-01 Procter & Gamble Pharma Compuestos de fosfonato que contienen nitrogeno cuaternario para tratar un metabolismo anormal del calcio y fosfato asi como el calculo y la placa dentales.
JPH07508279A (ja) * 1992-06-30 1995-09-14 プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド ホスホネート類及びｎｓａｉｄを含有した関節炎の治療用組成物
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
FR2703590B1 (fr) * 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
US20010007863A1 (en) * 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
US6008206A (en) * 1994-09-21 1999-12-28 Merck & Co., Inc. Sodium alendronate preparation for local administration
US20010051616A1 (en) * 1995-02-17 2001-12-13 David B. Karpf Method of lessening the risk of vertebral fractures
ATE309330T1 (de) * 1995-06-07 2005-11-15 Co Don Ag Verfahren zur osteoporosediagnose und zur testung potentieller osteoporose-therapeutika unter verwendung von standardisierten, primären osteoblastenzellkulturen aus osteoporotischen patienten
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
US6432932B1 (en) * 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6124314A (en) * 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
EP1088333A4 (en) * 1998-06-24 2005-08-10 Merck & Co Inc METHOD AND COMPOSITIONS FOR CONNECTING OSTEOPROSIS
IT1303672B1 (it) * 1998-07-28 2001-02-23 Nicox Sa Sali nitrati di farmaci attivi nei disordini ossei
EP0998932A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
EP0998933A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
JP3793023B2 (ja) * 1998-12-04 2006-07-05 ロシュ ダイアグノスティックス ゲーエムベーハー 体内プロテーゼの骨統合を促進するためのイバンドロネートの使用
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
WO2002005786A1 (fr) * 2000-07-17 2002-01-24 Yamanouchi Pharmaceutical Co., Ltd. Composition pharmaceutique a absorbabilite per os amelioree
CA2412373A1 (en) * 2000-07-19 2002-01-31 Eli Lilly And Company Method for enhancing bone mineral density gain
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
DK1372669T3 (da) * 2001-01-23 2005-10-17 Gador Sa Bisphosphonatholding sammensætning til forebyggelse og/eller behandling af metaboliske knoglesygdomme, fremgangsmåde til fremstilling af sådanne sammensætninger og anvendelse deraf
AR034199A1 (es) * 2001-02-01 2004-02-04 Riderway Corp Composicion farmacologica liquida para el tratamiento de enfermedades oseas y procedimientos para su elaboracion
SK9862003A3 (en) * 2001-02-06 2004-02-03 Royal Alexandra Hosp Children A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
BR0207871A (pt) * 2001-03-01 2004-06-22 Emisphere Tech Inc Composição para liberar bisfosfonato para um alvo
EP1387821A2 (en) * 2001-05-10 2004-02-11 Merck & Co., Inc. Estrogen receptor modulators
WO2003051373A1 (en) * 2001-12-13 2003-06-26 Merck & Co., Inc. Liquid bisphosphonate formulations for bone disorders
EP1455796A1 (en) * 2001-12-21 2004-09-15 The Procter & Gamble Company Method for the treatment of bone disorders
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
US7488496B2 (en) * 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
WO2003086415A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
DK1506041T3 (da) * 2002-05-10 2008-01-28 Hoffmann La Roche Inbandronsyre til behandling og forebyggelse af osteoporose
US20040188316A1 (en) * 2003-03-26 2004-09-30 The Procter & Gamble Company Kit for pharmaceutical use

Also Published As

Publication number Publication date
MA27157A1 (fr) 2005-01-03
AU2002360619A1 (en) 2003-07-15
TWI349553B (en) 2011-10-01
RU2004122433A (ru) 2005-03-10
PE20030743A1 (es) 2003-10-22
MY147886A (en) 2013-01-31
HUP0402267A3 (en) 2007-05-29
CZ2004690A3 (cs) 2004-09-15
CA2469779A1 (en) 2003-07-10
CN1723024A (zh) 2006-01-18
HUP0402267A2 (hu) 2005-02-28
WO2003055496A1 (en) 2003-07-10
SK2532004A3 (en) 2004-11-03
CN100479823C (zh) 2009-04-22
JP2005514400A (ja) 2005-05-19
TW200301704A (en) 2003-07-16
RU2294203C2 (ru) 2007-02-27
AR038041A1 (es) 2004-12-22
US20070166237A1 (en) 2007-07-19
CA2469779C (en) 2008-02-12
NO20043113L (no) 2004-09-01
KR20040065283A (ko) 2004-07-21
US20030118634A1 (en) 2003-06-26
US20080214505A1 (en) 2008-09-04
US20080260827A1 (en) 2008-10-23
US20080261924A1 (en) 2008-10-23
AU2002360619B2 (en) 2006-10-05
NO340249B1 (no) 2017-03-27
EP1455796A1 (en) 2004-09-15
HK1087039A1 (en) 2006-10-06
MXPA04006027A (es) 2004-09-27
IL162053A0 (en) 2005-11-20
IL162053A (en) 2009-09-22
NZ532994A (en) 2008-05-30
ZA200404007B (en) 2005-07-27
KR100638122B1 (ko) 2006-10-24

Similar Documents

Publication Publication Date Title
TW200603816A (en) Risedronate compositions and their methods of use
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
GR3033127T3 (en) Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
IL160028A (en) Thiophene carboxamide derivatives, process for their preparation, pharmaceutical compositions comprising them and their use in therapy
ZA953469B (en) New compound
HUP0203325A2 (hu) Biciklusos aminosavak, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
RU95102778A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования потерь костной ткани и снижения уровня холестерина в сыворотке, фармацевтический препарат, содержащий 2-фенил-3-ароилбензотиофен
CA2219115A1 (en) N-benzyl-3-indoleacetic acids as cyclooxygenase-2-inhibitors and antiinflammatory drugs
TW200744673A (en) Improved ibandronate formulations
PT1326613E (pt) Utilizacao de derivados de imidazo[1,2-a]piridin-,imidazo[1,2-a]pirimidin- e imidazo[1,2-a]pirazin-3-il-amina substituidos para a fabricacao de medicamentos para inibicao de nos
BG104476A (en) Therapeutical form for tolterodin with controlled release
SE9901573D0 (sv) New compounds
HK1087039A1 (en) Use of biphosphonate in preparing medical kit and a kit used for increasing bone mass
GB0130677D0 (en) Medicaments and novel compounds
CA2211320A1 (en) 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
GB2331926A (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
SE9901572D0 (sv) New compounds
MY160429A (en) 2, 5-disubstituted 3-mercaptopentanoic acid
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
CA2301590A1 (en) 2-aminopyridines as inhibitors of cyclooxygenase-2
ATE441653T1 (de) Phosphorenthaltende verbindugnen mit antithrombitische wirkung
DE69434002D1 (de) 2,3 diaryl-1-benzopyrame zur behandlung von dermatitis
HUP0300043A2 (en) Method and composition for the treatment of pain
GEP20043356B (en) Compounds Useful For Treatment or Prevention of Diseases Mediated By Alpha- 2B-Adrenoceptor
TH123055B (th) องค์ประกอบไรซีโดรเนต และวิธีของการใช้สารเหล่านี้

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)